Psoriatic Arthritis


Long-Term Ixekizumab Versus Adalimumab in Psoriatic Arthritis

November 10, 2020

In patients with psoriatic arthritis who are DMARD naïve, ixekizumab had similar efficacy at one year whether it was used as a monotherapy or in combination with methotrexate or csDMARD, while adalimumab showed better efficacy as a combination therapy.

Guselkumab Reduces Fatigue in Psoriatic Arthritis Patients

November 06, 2020

In a study that examined the effects of guselkumab (Tremfya, Janssen) on fatigue in patients with psoriatic arthritis, the treatment reduced fatigue through one year, according to researchers reporting at the annual meeting of the American College of Rheumatology on Friday.

Secukinumab Not Associated With Tuberculosis

October 02, 2020

Researchers writing in JAMA Dermatology report that latent tuberculosis infection previously assumed to be an adverse event as a result of treatment with secukinumab, is actually uncommon in patients with chronic systemic inflammatory conditions.

Only 12% of PsA Patients Say Disease Is Under Control

September 25, 2020

The use of biologics, JAK inhibitors and small molecule medications has become increasingly common for patients with psoriatic arthritis. Findings from the recent Psoriatic Arthritis In America 2020 survey by Health Union shows that of 1,120 patients surveyed, most patients (61 percent) are satisfied with the care they receive from their doctors, but they still struggle with flares and only 12 percent are satisfied with their care plan. In this interview, Brian Green, vice president of community development at Health Union, reviews the results of their latest survey.

The Future of Psoriatic Arthritis Treatment

September 23, 2020

New algorithms and more combination therapeutics are part of the future of psoriatic arthritis care. That’s according to Arthur Kavanaugh, M.D., a rheumatologist with UC San Diego Health who recently presented at the Congress of Clinical Rheumatology East annual meeting held this month.​

Striking the Right Balance in Psoriatic Arthritis Care

September 10, 2020

Treat-to-target strategies can be effective in addressing rheumatic diseases like psoriatic arthritis, but may not be enough on their own to single-handedly improve quality of life for those living with the disease, write physicians in a new article in Arthritis and Rheumatology.

Diabetes More Common in PsA Than RA

August 06, 2020

Researchers writing in Arthritis Care and Research this week report that rheumatoid arthritis patients actually have a lower rate of type 2 diabetes than people without RA or patients with hypertension, osteoarthritis and psoriatic arthritis.

Guselkumab Approved for Psoriatic Arthritis

July 14, 2020

The U.S. Food and Drug Administration has approved the first IL-23 inhibitor for moderate to severe psoriatic arthritis. The newly approved treatment, guselkumab, has been shown to improve the signs and symptoms of fatigue associated with PsA.

EULAR Report: Ixekizumab Approved for Axial Spondyloarthritis

June 04, 2020

Eli Lilly announced this week that Taltz (ixekizumab) has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of active non-radiographic axial spondyloarthritis (nr-axSpA). And, this week during the EULAR annual meeting, the company is reporting results from the 52-week SPIRIT phase 3b/4 trial for psoriatic arthritis comparing ixekizumab to adalimumab.

Apremilast Continues to Show Viability as Monotherapy

January 16, 2020

Psoriatic arthritis patients with moderate disease activity were more likely to reach treatment targets or low disease activity at week 52 with apremilast (Otezla, Celgene) than patients with high disease activity, researchers report in the January 7 issue of Arthritis Care and Research.

Secukinumab Benefits in Psoriatic Arthritis Persist for 5 Years

January 09, 2020

Secukinumab (Cosentyx, Novartis) provided sustained improvements through five years in the signs and symptoms of psoriatic arthritis with no new safety signals, say researchers recently writing in ACR Open Rheumatology.

Is Tofacitinib as Monotherapy Enough for Psoriatic Arthritis?

November 13, 2019

ACR Annual Meeting:  The use of methotrexate combined with or without the oral JAK inhibitor tofacitinib produced no clinically meaningful difference in 179 psoriatic arthritis patients from the OPAL Balance study, presented at ACR 2019 this week.

Guselkumab Safe, Efficient in Biologic-Naïve Patients with Active Psoriatic Arthritis

November 12, 2019

ACR Annual Meeting:  In patients with active psoriatic arthritis, who are biologic-naïve, guselkumab (Tremfya, Janssen) improved joint and skin symptoms, physical function, quality of life, and resolved enthesitis and dactylitis, according to a study presented at annual meeting of the American College of Rheumatology in Atlanta on November 12.